COVID-KOSHA
Home
Help
(current)
Comment
!
Note: Language translations may be imperfect
A model anti-pandemic portal for scientists & public
;
High priority articles (R1, Most articles most likely to be relevant):
Second priority articles (R2, Moderate portion of articles likely to be relevant):
Other articles (R3, Lesser portion of articles likely to be relevant):
Articles Not Curated -
Drug studies in humans
Last updated: 2024 Nov 18
Total hit(s): 7395
S.No.
PMID
Ascending order
Descending order
Title
Ascending order
Descending order
Journal Name
Ascending order
Descending order
Publish Date
Ascending order
Descending order
Impact Factor
Ascending order
Descending order
Citations
Ascending order
Descending order
1
39550106
Considerations for Coronavirus Disease 2019 Vaccination Among B-Cell-Depleted Patients.
Rheum Dis Clin North Am
2025 Feb
1
2
39550108
Flares of Systemic Autoimmune Rheumatic Disease Following Coronavirus Disease 2019 Vaccination: A Narrative Review.
Rheum Dis Clin North Am
2025 Feb
1
3
39182703
Diosmetin-7-O-beta-D-glucopyranoside from Pogostemonis Herba alleviated SARS-CoV-2-induced pneumonia by reshaping macrophage polarization and limiting viral replication.
J Ethnopharmacol
2025 Jan 10
6.8
1
4
39277919
SARS-CoV-2 detection in COVID-19 patients' sample using Wooden quoit conformation structural aptamer (WQCSA)-Based electronic bio-sensing system.
Biosens Bioelectron
2025 Jan 1
9.52
1
5
39313857
Immunogenicity and safety of an inactivated COVID-19 vaccine (CoronaVac(R)) co-administered with an inactivated enterovirus type 71 vaccine (Inlive(R)): A phase 4, randomized, controlled trial.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
6
38714327
Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
7
38512394
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
8
38575149
Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
9
39254005
Genomic insights into mRNA COVID-19 vaccines efficacy: Linking genetic polymorphisms to waning immunity.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
10
39397784
A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
11
39422261
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
12
38584118
Comparison of T cells mediated immunity and side effects of mRNA vaccine and conventional COVID-19 vaccines administrated in Jordan.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
13
38346223
Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
14
38073167
Assessing the quantity of neuropeptide Y in the serum of patients referred to Baqiyatallah Hospital with covid-19 concerning inflammatory factors following steroid therapy.
Acta Neurol Taiwan
2024 Dec 30
1
15
39524696
mRNA vaccine-induced IgG mediates nasal SARS-CoV-2 clearance in mice.
Mol Ther Nucleic Acids
2024 Dec 10
1
16
39259045
Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages.
Emerg Microbes Infect
2024 Dec
5.84
1
17
39262675
Co-infections of SARS-CoV-2 with respiratory syncytial virus and human influenza A in patients with symptoms of COVID-19 in Ghana: A retrospective study.
New Microbes New Infect
2024 Dec
1.6
1
18
39475004
Treatment with proton pump inhibitors is associated with secondary bacterial infections and sepsis in patients with COVID-19: a retrospective analysis of their joint impact on in-hospital prognosis.
Ann Med
2024 Dec
3.01
1
19
38882678
Dynamic expedition of leading mutations in SARS-CoV-2 spike glycoproteins.
Comput Struct Biotechnol J
2024 Dec
5.11
1
20
39468707
The characteristics of TCR CDR3 repertoire in COVID-19 patients and SARS-CoV-2 vaccine recipients.
Virulence
2024 Dec
4.81
1
21
38916498
"Outlaw" mutations in quasispecies of SARS-CoV-2 inhibit replication.
Emerg Microbes Infect
2024 Dec
5.84
1
22
38953857
A novel bispecific antibody targeting two overlapping epitopes in RBD improves neutralizing potency and breadth against SARS-CoV-2.
Emerg Microbes Infect
2024 Dec
5.84
1
23
39525081
Revealing SARS-CoV-2 M(pro) mutation cold and hot spots: Dynamic residue network analysis meets machine learning.
Comput Struct Biotechnol J
2024 Dec
5.11
1
24
38183475
Development of multiplex allele-specific RT-qPCR assays for differentiation of SARS-CoV-2 Omicron subvariants.
Appl Microbiol Biotechnol
2024 Dec
3.82
1
25
39188530
Structure of SARS-CoV-2 MTase nsp14 with the inhibitor STM957 reveals inhibition mechanism that is shared with a poxviral MTase VP39.
J Struct Biol X
2024 Dec
1